滤泡性淋巴瘤是最常见的恶性非何杰金淋巴瘤，由于这种疾病无法治愈，不断需要新的治疗方法。 最近批准的T细胞依赖性的双特异性抗体mosunetuzumab在复发或难治性滤泡性淋巴瘤患者中显示出有希望的结果和可管理的毒性。 与细胞免疫疗法选项相反，这种药物具有在不良特征患者中具有可耐受的细胞因子释放综合征、免疫效应细胞相关性神经毒性和传染性并发症的潜力。 鉴于PI3K抑制剂最近在市场上的撤回以及利用嵌合抗原受体T细胞（CAR-T）对某些患者的实际挑战，mosunetuzumab对患者和血液肿瘤学家来说都是一股清新之风。 需要更多数据来更好地定义这种分子的真正潜力，无论是单独使用还是与其他药物，包括抗体药物联络体，免疫调节剂和检查点抑制剂相结合。 未来的研究还将揭示mosunetuzumab与CAR-T的比较疗效，在设计良好的登记处或理想情况下的随机对照试验中。 ©2023 Lopedote和Shadman。

Follicular lymphoma is the most common indolent non-Hodgkin's lymphoma, and because of the incurable nature of this disorder, new therapies are constantly needed. The recently approved T-cell-dependent bispecific antibody mosunetuzumab showed promising results and manageable toxicities for patients with relapsed or refractory follicular lymphoma. Namely, as opposed to cellular immunotherapy options, this agent has the potential of being effective in patients with unfavorable features with a tolerable rate and severity of cytokine release syndrome, immune effector cell-associated neurotoxicity, and infectious complications. Given the recent withdrawal from the market of PI3K inhibitors and the practical challenges in utilizing with chimeric antigen receptor T-cells (CAR-T) for some patients, mosunetuzumab represents a "breath of fresh air" for both patients and hemato-oncologists. More data are required to better define the real potential of this molecule, either alone or in combination with other agents, including antibody drug conjugates, immunomodulators, and checkpoint inhibitors. Future studies will also shed light on the efficacy of mosunetuzumab compared with CAR-T, in well-designed registries or ideally in randomized controlled trials.© 2023 Lopedote and Shadman.